雷莫芦单抗(RAM)和紫杉醇是转移性胃食管腺癌患者二线标准治疗方案。我们报道了在含铂类或氟尿嘧啶类化疗失败后,FOLFIRI联合RAM对比紫杉醇联合RAM的安全性和有效性。 这是一项研究者发起的多中心II期临床试验,胃食管腺癌患者随机到FOLFIRI联合RAM组(A组)或紫杉醇联合RAM组(B组)。主要终点为6个月OS率,若A组6个月O...
目的 雷莫芦单抗(RAM)和紫杉醇是转移性胃食管腺癌患者二线标准治疗方案。我们报道了在含铂类或氟尿嘧啶类化疗失败后,FOLFIRI联合RAM对比紫杉醇联合RAM的安全性和有效性。 方法 这是一项研究者发起的多中心II期临床试验,胃食管腺癌患者随机到...
RAMBevacizumab-naiveEGFRColorectal cancerPurpose Few data of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (RAM) obtained in bevacizumab-naïve patients in clinical trials or routine clinical practice are available...doi:10.1007/s00280-019-03855-wSpringer...
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study. 来自 Wolters Kluwer 喜欢 0 阅读量: 3 摘要: 4023 Background: Ramucirumab as monotherapy and in ...
Introduction: The aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal adenocarcinoma (GEA). Methods: A systematic...
advanced or metastaticNSCLC(VITAL study: NCT00532155) as a second-line treatment withdocetaxelalso had no increase in OS with the addition of aflibercept (median, 10.1 months vs. 10.4 months) (Ramlau et al., 2012). Some other studies that produced similar results in OS with the aflibercept ...
FOLFIRI+ramucirumab与紫杉醇+ramucirumab作为二线治疗有或无多西紫杉醇的晚期或转移性胃食管腺癌患者--来自AIO的德国胃癌研究小组的II期RAMIRIS研究结果相关领域 催眠药 福尔菲里 医学 多西紫杉醇 内科学 临床终点 转移性乳腺癌 危险系数 人口 临床研究阶段 紫杉醇 肿瘤科 化疗 胃肠病学 外科 癌症 置信区间 随机对照...
folinate/5-fluorouracil(FOLFIRI)fortreating advancedcolorectalcancer:Aclinicalstudy 12111 Bao-LinLi,Xiao-LingHu,Xiao-HuiZhao,Hong-GeSun,Cai-YunZhou, YinZhang1 1DepartmentofOncology,theFirstAffiliatedHospitalofLiaoningMedicalUniversity,Jinzhou,Liaoning,, ...
Introduction: The aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal adenocarcinoma (GEA). Method...
FOLFIRI plus ramucirumab(RAM)therapy has been reported to be effective and safe in the RAISE trial as second-line treatment for unresectable colorectal can... A Naito,M Imasato,K Iwamoto,... - 《Gan to Kagaku Ryoho Cancer & Chemotherapy》 被引量: 0发表: 2023年 Real-World Evidence on Sec...